CHATTANOOGA, Tenn.–(BUSINESS WIRE)–EirSystems, an emerging leader in developing software to safely and efficiently prescribe and dispense prescriptions, recently closed a seed funding round led by Solas BioVentures. Other investors included several Chain Reaction Boston investors led by Ken Mooney. With this funding, EirSystems will continue to build partnerships and grow its market share in the electronic prescription market.
“EirSystems’ innovation in the e-prescription market is unmatched. This technology will help physicians better serve the well-being of their patients with faster, more accurate information at their fingertips,” commented David Adair, MD, MBA, co-founder and CEO of Solas BioVentures.We fully support their growth and look forward to the future of the business.”
“We are thrilled to co-invest with Solas BioVentures in this round of funding for EirSystems,” said Eliza Petrow, Managing Director of Chain Reaction Boston.At Chain Reaction, our group of angel investors is focused on funding innovative blockchain-based solutions, including in healthcare, and EirSystems fits that profile perfectly.”
“We are extremely grateful to be working with Solas BioVentures and Chain Reaction to secure our latest round of funding. We believe that our partnership with Solas will enable EirSystems to forge more partnerships in the healthcare industry, allowing our product to grow rapidly over the next few years,” said EirSystems CEO Tyler Seaberg.Specifically, this funding will allow us to ramp up production, expand our support teams by hiring talent from the Chattanooga area, and in 2023 launch new product offerings for medication management and health claims. prescription drugs designed to have a significant impact on the prescription space.
EirSystems’ proprietary PAGR (Prescription Abuse Greatly Reduced) is an advanced software platform providing physicians and pharmacists with the tools they need to make the prescription process simple, safe and efficient for their patients. PAGR can be integrated or installed in any system and operates in an easy to use web interface.
EirSystems Inc. was founded in 2018 by brothers Ryan and Tyler Seaberg to provide physicians with a one-stop-shop for all of their prescription needs. Having been personally impacted by the opioid crisis, the brothers bring a unique vision and drive to solving today’s issues in the prescription market. To better understand and address these issues, Ryan and Tyler consult with several medical professionals and their father, David Seaberg, a doctor in his 30s.
EirSystems serves customers in many sectors of the healthcare market, including palliative care, home healthcare, small and medium clinics and telehealth platforms. This round of funding will be used to continue to grow their team and forge new partnerships to improve PAGR’s real-time benefits functionality to identify cheaper and safer drugs, and develop exciting new features. , including a drug management platform. The deployment of these new features is planned for 2023. For more information, visit www.eirsystems.net
About Solas BioVentures
Solas BioVentures is a venture capital firm that invests exclusively in the life sciences industry, focusing on early-stage and development-stage biotechnology and medical technology companies that are advancing impactful and disruptive technologies. Based in Chattanooga, Tennessee, its coverage is global. For more information, visit solasbio.com.
About the chain reaction
Chain Reaction is a Boston-based angel investor group that infuses innovative blockchain startups with fast funding, invaluable mentorship, and unparalleled networking opportunities. Investor members are committed to accelerating the investment process, generating strong returns, and strengthening the blockchain ecosystem across the United States. For more information, visit www.chainreactionboston.com.